Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewATPA is a selective and potent GluK1 (formerly GluR5) kainate receptor agonist (Ki = 4.3 nM), inactive at GluK6 (formerly GluR6) (Ki > 1 mM) and only weakly active at AMPA receptors (GluA1-4) and the kainate receptors GluK5 (formerly KA-2) and GluK3 (formerly GluR7) (Ki values of 6 - 14 μM).
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
分子量 | 228.25 |
公式 | C10H16N2O4 |
储存 | Desiccate at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 140158-50-5 |
PubChem ID | 2253 |
InChI Key | PIXJURSCCVBKRF-UHFFFAOYSA-N |
Smiles | CC(C)(C)C1=C(CC(N)C(O)=O)C(O)=NO1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 2.28 | 10 温和加热 | |
1eq. NaOH | 4.57 | 20 温和加热 |
以下数据基于产品分子量 228.25。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 21.91 mL | 109.53 mL | 219.06 mL |
1 mM | 4.38 mL | 21.91 mL | 43.81 mL |
2 mM | 2.19 mL | 10.95 mL | 21.91 mL |
10 mM | 0.44 mL | 2.19 mL | 4.38 mL |
参考文献是支持产品生物活性的出版物。
Clarke et al (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389 599 PMID: 9335499
Matzen et al (1997) AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazole bioisasteres of glutamic acid. J.Med.Chem. 40 520 PMID: 9046343
Moldrich et al (1999) Excitotoxic injury profiles of low-affinity kainate receptor agonists in neuronal cultures. Eur.J.Pharmacol. 378 R1 PMID: 10478637
If you know of a relevant reference for ATPA, please let us know.
关键词: ATPA, ATPA supplier, Selective, potent, GluR5, agonists, Glutamate, Kainate, Receptors, iGlur, Ionotropic, GluK1, 1107, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 ATPA 的部分引用包括:
Song et al (2015) MinCyc does not affect long-term potentiation in the anterior cingulate cortex of normal adult mice. Front Pediatr 11 25 PMID: 25933605
Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131
Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121 PMID: 18789344
Langner et al (2017) Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms. Neurochem Res 42 838 PMID: 27444613
Talpalar and Kiehn (2010) Glutamatergic mechanisms for speed control and network operation in the rodent locomotor CpG. Front Neural Circuits 4 PMID: 20844601
Liu et al (2004) Astrocyte-mediated activation of neuronal kainate receptors. Mol Pain 101 3172 PMID: 14766987
Xu et al (2006) Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2 29 PMID: 16948848
您是否知道使用了 Tocris ATPA 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review ATPA and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.